Alcon Inc. stays a Buy with strong FDA approvals, growth, and undervalued stock potential.

Alcon Inc. remains a strong Buy due to recent FDA approvals, acquisitions expanding its portfolio, and steady long-term demand in eyecare. The company shows consistent revenue growth, improved earnings guidance, and a promising pipeline targeting critical eye diseases like glaucoma and macular degeneration. Its strong balance sheet with low debt and attractive valuation metrics suggest potential for double-digit earnings growth and about 21% stock price upside. These factors make Alcon an appealing investment despite recent market underperformance.

Alcon AG has a market cap of $32.59 billion and a dividend yield of 0.53% as of Oct 21, 2026 23:01 WIB on Pluang. Despite the recent bullish outlook and growth in its eyecare portfolio, the stock price is slightly down by 0.32% at USD 67.61. Trading volume stands at 978,633 shares with a typical hold time of 71 days, while Pluang order activity shows a strong sell sentiment at 97%.